Skip to main content
Premium Trial:

Request an Annual Quote

Gen-Probe, BioMerieux Pen Three Technology Agreements

NEW YORK, Oct. 7 (GenomeWeb News) - Gen-Probe and BioMerieux have signed three agreements in which Gen-Probe will pay for access to BioMerieux's blood clot-related biomarkers for blood clotting disorders, Gen-Probe will gain negotiation rights for access to the BioMerieux Nuclisens EasyQ platform, and BioMerieux will have access to Gen-Probe's ribosomal RNA markers, said BioMerieux in a statement today.

 

Gen-Probe will pay $1 million to use the blood clot-related biomarkers "to develop tests that detect mutations in the genes that code for factor V and prothrombin," which are proteins that control the blood clotting process, said the statement.

 

Under the Nuclisens EasyQ platform arrangement, Gen-Probe may negotiate to "develop TMA amplified assays complementary to bioMerieux product lines" for further distribution by BioMerieux, the statement said.

 

BioMerieux will pay $250,000 for a limited research license and an option to develop diagnostic products, using Gen-Probe's ribosomal RNA markers, said BioMerieux. If the option is exercised, BioMerieux may as much as $7.5 million, "depending on the number of the targets exercised," the statement said. Under the licenses, Gen-Probe will also receive royalties on the sale of products developed using its technology, the statement added.

 

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.